Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this study involving 15 women with alopecia, subcutaneous scalp injections of platelet-rich plasma every four weeks for three sessions led to increased hair and hair follicle density at 24 weeks, with common side effects being local swelling and pain.

This study found that platelet-rich plasma improved healing and accelerated scar maturation in rat models of second-degree skin burns, especially noticeable after four weeks of treatment.

This study introduced a new technique, 2Phatal, enabling precise apoptotic cell ablation in living animals, revealing unique cell-type differences in apoptosis-related dynamics.

This study found that platelet-rich plasma therapy may improve symptoms and quality of life in adults with moderate to severe atopic dermatitis, although standardized protocols for its preparation need further study.

In this study, platelet-rich plasma treatment showed minimal effectiveness for Alopecia Areata but was more effective than no treatment, with a 20% improvement observed compared to 3.3% in the control group.

This review discusses the diagnosis and management of acquired haemophilia and reports no new findings; the authors highlight the importance of early diagnosis to reduce mortality.

This study found that sonicated platelet-rich plasma was more effective than calcium chloride-induced platelet-rich plasma in activating hair follicle stem cells and promoting hair follicle regeneration in mice.

This study discusses the potential psychological impact of platelet-rich plasma treatment for hair loss but reports no standardized protocols or conclusive results, highlighting the need for further analysis.

This study found that psoriasis patients on biologic therapy had significantly lower anti-COVID19 IgG antibody levels after vaccination compared to healthy individuals not on biologic treatment.

This study provides evidence that innate lymphoid cells-type 1 can induce alopecia areata in human hair follicles, challenging the view that it is solely a CD8+ T cell-driven autoimmune disease.

This study found differential expression of growth factors and cytokines in umbilical cord blood-derived platelet-rich plasma, with the highest concentrations observed in the B blood type, but also noted weak correlations with ABO blood groups, suggesting other influencing factors.

This review discusses the modern production methods, mechanisms of action, and various uses of platelet-rich plasma in medicine, highlighting promising applications but noting the need for more high-quality research.

In this study, platelet-rich plasma significantly increased hair regrowth and reduced symptoms of alopecia areata compared to triamcinolone acetonide or placebo, with no observed side effects.

A skin condition called pyodermatitis vegetans was found in a patient with multiple myeloma for the first time.

This study reviews current methods for making and using platelet-rich plasma and fibrin, emphasizing the variability in clinical outcomes due to differences in preparation protocols, and calls for standardized guidelines and large-scale studies for better effectiveness in regenerative medicine.

This study found that ALRN-6924 effectively protected human hair follicles from cyclophosphamide-induced damage in an ex vivo setting, suggesting it may reduce both acute and permanent chemotherapy-induced alopecia.

In this laboratory study, researchers found that human platelet-rich plasma (hPRP) significantly improved the proliferation and hair-inductive capacity of human dermal papilla cells (hDPCs) compared to fetal bovine serum, suggesting hPRP as a potential substitute for FBS in expanding hDPCs for clinical hair regeneration therapies.

In this study, hair-follicle-associated pluripotent stem cell implantation improved functional recovery and reduced inflammation in a mouse model of intracerebral hemorrhage.

This review discusses platelet-rich plasma and cell-based therapies for hair loss, noting promising results but emphasizing the need for standardization and robust trials to confirm their efficacy.

In this study, four dogs with a novel skin disease showed clinical lesions involving verrucous, crusted papules and plaques, and responded variably to immunosuppressive therapy, suggesting an immune-mediated cause.

Fibroblasts from healthy donors can prevent changes seen in recessive epidermolysis bullosa simplex.

In vivo using the C3H mouse model, this study observed that BST2 expression occurs before hair loss in alopecia areata and is followed by an increase in epidermal γδ T cell numbers.

This case report details a 27-year-old woman's diagnosis of systemic lupus erythematosus with immune-mediated intravascular haemolysis, which improved with steroid treatment.

This review found mixed evidence regarding platelet-rich plasma's effectiveness in various medical applications, noting significant limitations like small sample sizes and lack of standardization that necessitate further research.

The study suggests that immune privilege collapse in bulge cells and the involvement of pro-inflammatory cytokine interferon-γ contribute to hair follicle stem cell loss in lichen planopilaris.

This study found that a novel IKZF1 mutation, p.L188V, is linked to juvenile-onset systemic lupus erythematosus and alters B-cell activation by disrupting normal DNA binding.

This study identified CD28, GZMB, and CD1C as key immune regulators in alopecia areata, highlighting CD28 as a potential therapeutic target with a promising safety profile, using a proteome-anchored multi-omics approach to uncover actionable targets for this autoimmune hair-loss disorder.

This study found that high leukocyte platelet-rich plasma was more effective in increasing hair density and patient satisfaction for androgenetic alopecia treatment.

This study identified CD28 as a potential drug target in treating alopecia areata by linking immune signaling pathways to local inflammation, highlighting belatacept as a promising treatment option due to minimal adverse effects and providing insights into autoimmune target discovery.